Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Pharmacy World & Science

• Publication date

  1995-03-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01875051PMID 7795555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Zidovudine

  2012cited by this paper
• Zalcitabine

  2012cited by this paper
• Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal

  2004cited by this paper
• Didanosine Compared with Continuation of Zidovudine in HIV-infected Patients with Signs of Clinical Deterioration While Receiving Zidovudine

  1994cited by this paper
• Pharmacokinetics of Zidovudine and Metabolites in a Patient with HIV-Associated Nephropathy and Severe Renal Impairment

  1994cited by this paper
• The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group.

  1993cited by this paper
• Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome

  1993cited by this paper
• Therapy for human immunodeficiency virus infection.

  1993cited by this paper
• Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS

  1993cited by this paper
• Comparative Pharmacokinetics of Antiviral Nucleoside Analogues

  1993cited by this paper
• Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy

  1993cited by this paper
• The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082)

  1993cited by this paper
• Erratic zidovudine bioavailability in HIV seropositive patients.

  1993cited by this paper
• Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection

  1993cited by this paper
• 2',3'-dideoxyinosine (ddI): its chemical stability and cyclodextrin complexation in aqueous media.

  1993cited by this paper
• Transfer and metabolism of dideoxyinosine by the perfused human placenta.

  1993cited by this paper
• Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.

  1993cited by this paper
• Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.

  1993cited by this paper
• Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV

  1993cited by this paper
• Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.

  1993cited by this paper
• Zalcitabine

  1993cited by this paper
• Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

  1992cited by this paper
• Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis

  1992cited by this paper
• A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

  1992cited by this paper
• The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.

  1992cited by this paper
• Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection

  1992cited by this paper
• Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure

  1992cited by this paper
• Comparative Pharmacokinetics of Zidovudine in Healthy Volunteers and in Patients With AIDS With and Without Hepatic Disease

  1992cited by this paper
• Glucuronidation of Drugs

  1992cited by this paper
• Relationship between Dideoxyinosine Exposure, CD4 Counts, and p24 Antigen Levels in Human Immunodeficiency Virus Infection

  1992cited by this paper
• Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen.

  1992influential reference
• Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus.

  1992cited by this paper
• Clinical pharmacokinetics of 3′‐azido‐3′‐deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′‐amino‐3′‐deoxythymidine

  1992cited by this paper
• Pharmacokinetics of zidovudine in end‐stage renal disease: influence of haemodialysis

  1992cited by this paper
• Extrahepatic metabolism of zidovudine.

  1992cited by this paper
• Zidovudine Pharmacokinetics During Pregnancy

  1992cited by this paper
• Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

  1992cited by this paper
• Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

  1992cited by this paper
• Didanosine

  1992cited by this paper
• Concentrations of Phosphorylated Zidovudine (ZDV) in Patient Leukocytes Do Not Correlate with ZDV Dose or Plasma Concentrations

  1991cited by this paper
• A method for the quantification of intracellular zidovudine nucleotides.

  1991cited by this paper
• Food‐induced reduction in bioavailability of didanosine

  1991cited by this paper
• Pharmacokinetic disposition of zidovudine during pregnancy.

  1991cited by this paper
• Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients.

  1991cited by this paper
• Fetoplacental passage of 2',3'-dideoxyinosine.

  1991cited by this paper
• Population pharmacokinetics of zidovudine

  1990cited by this paper
• Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high‐fat meal

  1990cited by this paper
• Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.

  1990cited by this paper
• Pharmacokinetics of zidovudine in patients with liver cirrhosis

  1990cited by this paper
• Zidovudine disposition in patients with severe renal impairment: Influence of hemodialysis

  1989cited by this paper
• The pharmacokinetics of zidovudine administered by continuous infusion in children.

  1989cited by this paper
• Preformulation solubility and kinetic studies of 2',3'-dideoxypurine nucleosides: potential anti-AIDS agents

  1988cited by this paper
• The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.

  1987cited by this paper

• Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics

  2020cites this paper
• SIMPLE SPECTROPHOTOMETRIC ASSAY AND BIOLOGIACL EVALUATION OF ZALCITABINE

  2017influential citation
• Neuropsychiatric Effects of HIV Antiviral Medications

  2016cites this paper
• Uridine Abrogates the Adverse Effects of Antiretroviral Pyrimidine Analogues on Adipose Cell Functions

  2006cites this paper
• Effect of Azidothymidine on CD4 Positive T Cells in HIV

  2004cites this paper
• The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro

  2004cites this paper
• Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

  2003cites this paper
• Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters

  2003cites this paper
• Clinical Implications of CNS Penetration of Antiretroviral Drugs

  2002cites this paper
• Didanosine once daily: potential for expanded use

  2000cites this paper
• Pharmacological Exposure and the Development of Drug Resistance in HIV

  2000cites this paper
• Therapeutic and toxic blood concentrations of more than 500 drugs.

  1997cites this paper
• The entry of antiviral and antiretroviral drugs into the central nervous system.

  1997cites this paper
• Didanosine

  1996cites this paper
• Pharmacokinetic Individualisation of Zidovudine Therapy

  1996cites this paper
• Bioanalysis and clinical pharmacokinetics of antiretroviral agents in HIV-infected individuals

  1995cites this paper